Comment on "Apixaban vs. aspirin for stroke prevention in people with subclinical atrial fibrillation and a history of stroke or transient ischemic attack: subgroup analysis of the ARTESiA randomized controlled trial"
I read with interest the subgroup analysis of the ARTESiA trial recently published in Lancet Neurology....
Saved in:
| Main Author: | Vittorio Pengo |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
PAGEPress Publications
2025-04-01
|
| Series: | Bleeding, Thrombosis and Vascular Biology |
| Subjects: | |
| Online Access: | https://www.btvb.org/btvb/article/view/179 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
THE PHARMACOKINETICS OF APIXABAN IN PATIENTS WITH CARDIOEMBOLIC STROKE IN ACUTE PHASE
by: A. V. Kryukov, et al.
Published: (2016-06-01) -
Efficacy and safety of apixaban and warfarin in prevention of ischemic stroke: a systematic review and meta-analysis
by: Wei Gu, et al.
Published: (2022-04-01) -
CLINICAL AND ECONOMICAL COMPARISON OF RIVAROXABAN AND APIXABAN USE IN PATIENTS WITH NON-VALVULAR ATRIAL FIBRILLATION
by: S. V. Nedogoda, et al.
Published: (2017-03-01) -
Exploring Apixaban Pharmacokinetics, Pharmacodynamics, and Safety in Hemodiafiltration Patients
by: Aurema Otero, et al.
Published: (2024-09-01) -
THE OPPORTUNITIES FOR RISK REDUCTION OF RECURRENT STROKE IN ATRIAL FIBRILLATION
by: I. L. Davydkin, et al.
Published: (2015-06-01)